A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors

In brief

The study is being conducted to evaluate the efficacy, and safety of SHR-2017 Injection in Patients with Bone Metastases from Solid Tumors. To explore the reasonable dosage of SHR-2017 Injection for Bone Metastases from Solid Tumors

Key facts

Study ID

NCT07028268

Run by

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

People needed

210

Starts

2025-06-24

Expected to finish

2027-05-01

Last updated by the study team

2025-12-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able and willing to provide a written informed consent；
• Male or female, ≥18 years of age；
• Histologically or cytologically confirmed solid tumors；
• At least 1 bone metastasis demonstrated by radiologic imaging or histopathology；
• Eastern Cooperative Oncology Group performance Status≤2。
• Life expectancy was judged by the investigators to be at least 6 months;
• Adequate organ function at Screening
• Female subjects with a negative blood pregnancy test and are not breastfeeding

You may not qualify if…

• Pre-existing or comorbid related oral diseases or oral cavity requiring surgery, etc；
• History of major joint (e.g., hip, knee, or shoulder) trauma or surgery prior to the first dose of the drug；
• Received radiotherapeutic drugs or bone radiotherapy prior to the first study drug administration
• Any cardiovascular disease for which the investigator considers the subject unfit to participate in the study
• resting tachycardia or resting bradycardia;
• The subject's pain is predominantly from pain unrelated to the bone metastases;
• Subject is unable to perform a pain assessment;
• Symptomatic or treatment-requiring brain metastases or other central nervous system metastases
• Comorbid infectious disease
• Prior receipt of exogenous nerve growth factor or anti-nerve growth factor antibodies;
• Prior history of allergy to relevant drug ingredients or components;
• Participation in other clinical trials within a certain period of time
• Subjects who, in the opinion of the investigator, have any other factors

Where it is running

• Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.